The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 381-390

  Jonsdottir, Kristin ^a   Zhang, Hui ^a   Jhagroe, Darshni ^b   Skaland, Ivar ^a   Slewa, Aida ^a   Björkblom, Benny ^a   Coffey, Eleanor T ^c   Gudlaugsson, Einar ^a   Smaaland, Rune ^a   Janssen, Emiel A M ^a   Baak, Jan P A ^a,d  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Breast cancer; Lymph node negative; MARCKSL1; Proliferation

Indexed keywords

ESTROGEN RECEPTOR; HISTONE H3; MARCKS PROTEIN; MESSENGER RNA; MYRISTOYLATED ALANINE RICH C KINASE SUBSTRATE LIKE 1 PROTEIN; PHOSPHOHISTONE H3; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; DISTANT METASTASIS; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE NEGATIVE BREAST CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HISTONES; HUMANS; KAPLAN-MEIER ESTIMATE; KERATINS, TYPE II; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866564789     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2155-9     Document Type: Article

References (30)

1. Early Breast cancer Trialists' collaborative group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717. doi:10.1016/ S0140-6736(05)66544-0
2. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23(25):5993-6001. doi:10.1200/JCO.2005. 05.511
3. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P (2003) Compensation mechanism in tumor cell migration: mesenchymalamoeboid transition after blocking of pericellular proteolysis. J Cell Biol 160(2):267-277. doi:10.1083/jcb.200209006 (Pubitemid 36254960)
4. Pandey PR, Saidou J, Watabe K (2010) Role of myoepithelial cells in breast tumor progression. Front Biosci 15:226-236
5. Yue L, Lu S, Garces J, Jin T, Li J (2000) Protein kinase C-regulated dynamitin-macrophage-enriched myristoylated alaninerice C kinase substrate interaction is involved in macrophage cell spreading. J Biol Chem 275(31):23948-23956. doi:10.1074/jbc. M001845200 (Pubitemid 30624683)
6. Arbuzova A, Schmitz AA, Vergeres G (2002) Cross-talk unfolded: mARCKS proteins. Biochem J 362(Pt 1):1-12 (Pubitemid 34174456)
7. Blackshear PJ, Verghese GM, Johnson JD, Haupt DM, Stumpo DJ (1992) Characteristics of the F52 protein, a MARCKS homologue. J Biol Chem 267(19):13540-13546
8. Li J, Aderem A (1992) MacMARCKS, a novel member of the MARCKS family of protein kinase C substrates. Cell 70(5):791-801. doi:10.1016/0092-8674(92)90312- Z
9. Lobach DF, Rochelle JM, Watson ML, Seldin MF, Blackshear PJ (1993) Nucleotide sequence, expression, and chromosomal mapping of Mrp and mapping of five related sequences. Genomics 17(1):194-204. doi:10.1006/geno.1993.1301 (Pubitemid 23205076)
10. McNamara RK, Stumpo DJ, Morel LM, Lewis MH, Wakeland EK, Blackshear PJ, Lenox RH (1998) Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: transgenic rescue and interactions with gene background. Proc Natl Acad Sci USA 95(24):14517-14522
11. Stumpo DJ, Eddy RL Jr, Haley LL, Sait S, Shows TB, Lai WS, Young WS 3rd, Speer MC, Dehejia A, Polymeropoulos M, Blackshear PJ (1998) Promoter sequence, expression, and fine chromosomal mapping of the human gene (MLP) encoding the MARCKS-like protein: identification of neighboring and linked polymorphic loci for MLP and MACS and use in the evaluation of human neural tube defects. Genomics 49(2):253-264. doi: 10.1006/geno.1998.5247 (Pubitemid 28240692)
12. Myat MM, Chang S, Rodriguez-Boulan E, Aderem A (1998) Identification of the basolateral targeting determinant of a peripheral membrane protein, MacMARCKS, in polarized cells. Curr Biol 8(12):677-683 (Pubitemid 28286274)
13. Hartwig JH, Thelen M, Rosen A, Janmey PA, Nairn AC, Aderem A (1992) MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature 356(6370):618-622. doi:10.1038/356618a0
14. Guo Y, Singleton PA, Rowshan A, Gucek M, Cole RN, Graham DR, Van Eyk JE, Garcia JG (2007) Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphateinduced barrier enhancement. Mol Cell Proteomics 6(4):689-696. doi:10.1074/mcp.M600398-MCP200 (Pubitemid 46630101)
15. Wang J, Jarrett J, Huang CC, Satcher RL Jr, Levenson AS (2007) Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. Clin Exp Metastasis 24(6):411-422. doi:10.1007/s10585-007-9078-6 (Pubitemid 47367683)
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067-9072. doi:10.1200/ JCO.2004.01.0454
17. World Health Organization (1981) Histologic typing of breast tumors, 2nd edn. World Health Organization, Geneva
18. Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS, Los J, Peterse HC et al (1989) The multicenter morphometric mammary carcinoma project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 185(5):664-670 (Pubitemid 20076937)
19. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP (2009) Validating the prognostic value of proliferation measured by phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat 114(1):39-45. doi:10.1007/s10549-008-9980-x
20. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP (2007) Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 20(12):1307-1315. doi:10.1038/ modpathol.3800972 (Pubitemid 350126856)
21. Bol MG, Baak JP, Rep S, Marx WL, Kruse AJ, Bos SD, Kisman O, Voorhorst FJ (2002) Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. Urology 60(6):1124-1130 (Pubitemid 35447592)
22. Skaland I, Janssen EA, Gudlaugsson E, Hui Ru, Guo L, Baak JP (2009) The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer. Cell Oncol 31(4):261-271. doi:10.3233/CLO-2009-0464
23. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH (2011) starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res 39(Database issue):D202-D209. doi:10.1093/ nar/gkq1056
24. van den Bout I, Truong HH, Huveneers S, Kuikman I, Danen EH, Sonnenberg A (2007) The regulation of MacMARCKS expression by integrin beta3. Exp Cell Res 313(6):1260-1269. doi: 10.1016/j.yexcr.2007.01.005 (Pubitemid 46427817)
25. van den Bout I, van Rheenen J, van Angelen AA, de Rooij J, Wilhelmsen K, Jalink K, Divecha N, Sonnenberg A (2008) Investigation into the mechanism regulating MRP localization. Exp Cell Res 314(2):330-341. doi:10.1016/j.yexcr. 2007.08.019 (Pubitemid 350216095)
26. Techasen A, Loilome W, Namwat N, Takahashi E, Sugihara E, Puapairoj A, Miwa M, Saya H, Yongvanit P (2010) Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci 101(3):658-665. doi: 10.1111/j.1349-7006.2009.01427.x
27. Finlayson AE, Freeman KW (2009) A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis. PLoS One 4(11):e7833. doi:10.1371/journal. pone.0007833
28. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1(4):304-313
29. Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, Uhlen M, Nilsson P (2009) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10:365. doi:10.1186/1471-2164-10-365
30. Mattick JS, Makunin IV (2006) Non-coding RNA. Hum Mol Genet 15(spec no 1):R17-R29. doi:10.1093/hmg/ddl046